Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis Meeting Abstract
| Authors: | Mascarenhas, J.; Maher, K. R.; Rampal, R.; Bose, P.; Podoltsev, N. A.; Hong, J.; Wang, X.; Kye, S.; Harrison, C. |
| Abstract Title: | Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406331 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS6594 |
| Notes: | Meeting Abstract: TPS6594 -- Source: Wos |
